Chiesi Group Announces New Chair and Vice Chair
Highlights:
Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations
Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy
Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair.
During his mandate, Alessandro Chiesi oversaw the Group through a phase of continued international development and governance strengthening, thereby further consolidating Chiesi’s long-term strategy as a research focused biopharmaceutical company and certified B Corp.
“It has been my privilege to serve as Chair during a period of evolution for Chiesi,” said Alessandro Chiesi. “What has remained unchanged is the Group’s firm roots in our clear values, strong sense of responsibility, and long-term vision. On behalf of the Board and personally, I congratulate Maria Paola on her appointment and offer her our collective support. I am honored to assume the Vice Chair role, and I will continue working to support Chiesi in advancing its stated objectives.”
The Board has unanimously appointed Maria Paola Chiesi as Chair, effective immediately. As a member of the Chiesi family and Board, and through her operational roles over the last 30 years, she has played a central role in shaping the Group’s strategic planning and in embedding sustainability as a core driver of business decisions. This appointment also marks an important milestone in the Group’s history, as she becomes the first woman Chair of Chiesi.
“I take on this new role with a deep sense of accountability, and with the aim to reinforce our continuity and commitment to the values that have guided Chiesi through generations,” said Maria Paola Chiesi. “For us, science that cares means pursuing scientific innovation with responsibility for its impact on people, society and the environment. As ever, this principle underpins our identity as a Benefit Corporation and B Corp, and it makes sustainability an integral part of our business model, embedded in how we make decisions and create long-term value for patients, communities and future generations.”
This transition reflects the Board’s intention to maintain stability and coherence in governance, while continuing to align growth, innovation, and sustainability through a long-term, multigenerational perspective.
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet verified standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com
Contacts
Press Info:
Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com
Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com
Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy
- 西藏智汇矿业登陆港股:从高原走向国际 独特资源禀赋释放长期增长潜力
- 远程光伏轻卡发布 引领行业科技之“光”
- 积极建设青年创新创业生态圈,广州大学城产学研一体化持续发力!
- 古玩精品推荐
- Visa and Western Union Announce Expanded Collaboration Transforming How Money Travels Cross-Border
- 一站式医药信息平台,辽宁初恒科技助您开启智享新篇
- 波司登业绩稳健高质量增长 连续8年创历史新高
- 数字化技术加速发展 长虹美菱工厂正全面升级
- Intesa Sanpaolo Leads in Europe for Relations with Investors and Analysts and for Best ESG Program
- 《双面千金洛莞莞》甜蜜来袭 王煜霖青春演绎大理寺捕快
- 一座甜了千年的城,黄岩文旅冉冉出圈
- “2024福布斯中国白酒品牌评选”正式签约
- EBC Financial Group 进军南非,加速推进非洲战略布局
- 国泰君安国际MSCI ESG评级获提升至A级 可持续发展表现卓越
- 著名国学易经大师---李春
- Sportradar Announces Pricing of Public Offering of Class A Ordinary Shares by Selling Shareholders a
- 刘诗诗《掌心》哭戏感染力超绝,情绪戏层次分明,演技再获认可
- 品牌蓄势待发:NIQ揭示2025年表现最佳创新背后的策略
- 瑞凯谱头皮抗衰新趋势:双专利科技赋能,从“头”开启抗衰新蓝海
- “青领杯”大学生创新创业大赛走进江西两所高校
- 全链协同 绿色共生——邦邦汽服携手吉利循环产业中心 解锁汽车后市场绿色循环新路径
- 双奖加冕!益芽口腔陈奇院长荣膺隐适美隐形矫正亚太区Top Provider称号!
- Capvidia和Hexagon将联合举办线上研讨会,探讨如何利用MBD、QIF和PC-DMIS构建从设计到检测的“真正”数字主线
- 李克勤披荆斩棘二公全新组队 首次挑战京剧旦角“虞姬”反转魅力
- 大族光子推出“Pro Cut”系列无毛刺切割光纤激光器
- 创维光伏光储盈|山东小微企业主正在用的“光伏储能”省电方案
- IPS 2026 与 Binghatti 加强合作,携手推动中东地区品牌豪华房地产发展
- 医产协同助力成果转化,2024北京城市副中心创新医学转化大赛圆满落幕
- 月满中秋,A.O.史密斯好风好水健康厨房神器加持畅享品质生活
- Nyxoah to Participate in the Jefferies Global Healthcare Conference





